

Megan K Herbert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7946786/publications.pdf>

Version: 2024-02-01

24
papers

1,342
citations

516215

16
h-index

580395

25
g-index

28
all docs

28
docs citations

28
times ranked

2526
citing authors

#	ARTICLE	IF	CITATIONS
1	Cis P-tau underlies vascular contribution to cognitive impairment and dementia and can be effectively targeted by immunotherapy in mice. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	34
2	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611.	0.9	17
3	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
4	Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. <i>Journal of Hematology and Oncology</i> , 2018, 11, 73.	6.9	23
5	Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. <i>Nature Communications</i> , 2018, 9, 3069.	5.8	116
6	Immune Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	2.9	41
7	Cytosolic 5 α -nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 862-868.	0.5	71
8	Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. <i>Nature Communications</i> , 2017, 8, 1000.	5.8	103
9	Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegeneration. <i>Cell and Bioscience</i> , 2016, 6, 59.	2.1	35
10	Potential of the Antibody Against <i>cis</i> -Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. <i>JAMA Neurology</i> , 2016, 73, 1356.	4.5	64
11	Disease specificity of autoantibodies to cytosolic 5 α -nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.5	116
12	Novel serology testing for sporadic inclusion body myositis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 595-600.	2.0	22
13	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. <i>Frontiers in Neurology</i> , 2015, 6, 91.	1.1	60
14	Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. <i>Neurobiology of Aging</i> , 2015, 36, 1271-1273.	1.5	16
15	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. <i>BBA Clinical</i> , 2015, 4, 1-6.	4.1	2
16	CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 112-115.	1.1	70
17	Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. <i>Alzheimer's and Dementia</i> , 2014, 10, 448.	0.4	23
18	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. <i>Journal of Neurology</i> , 2013, 260, 3129-3133.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. <i>Journal of Immunological Methods</i> , 2012, 381, 1-8.	0.6	4
20	Limited expression of heparan sulphate proteoglycans associated with A β deposits in the APP ^{swe} /PS1 ^{dE9} mouse model for Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2010, 36, 478-486.	1.8	11
21	Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 347-354.	1.1	7
22	Effect of CYP2D6 metabolizer status on the disposition of the (+) and (âˆ-) enantiomers of perhexiline in patients with myocardial ischaemia. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 305-312.	0.7	10
23	Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 832, 114-120.	1.2	17
24	Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 843, 302-309.	1.2	12